Rarity PBC

Rarity PBC, based in Los Angeles, US, focuses on the development of gene therapies designed to treat rare genetic disorders, addressing the root causes of diseases through innovative genetic modifications. Founded in 2023, Rarity PBC specializes in gene therapy development aimed at rare diseases. The company has engaged in a Seed funding round in which it raised USD 4. 6 mn.

The latest funding round took place on October 29, 2025, with this round being the only deal reported to date. Rarity PBC specializes in the development of innovative gene therapies aimed at treating rare diseases. Their core offerings focus on modifying or replacing defective genes to correct underlying genetic issues, thereby addressing the root causes of diseases rather than merely alleviating symptoms. By delivering accurate genetic instructions to targeted cells, Rarity's therapies facilitate the proper production of proteins necessary for normal bodily functions.

These solutions are designed for a diverse range of patient needs and aim to provide lasting, potentially curative outcomes. Rarity's primary market includes patients suffering from rare genetic disorders, with a commitment to ensuring accessibility and affordability across various geographical regions, including North America and Europe. Revenue generation at Rarity PBC is derived from partnerships with healthcare institutions and direct collaborations with pharmaceutical companies focused on the commercialization of their gene therapy products. The transaction structure typically involves contract agreements whereby healthcare providers gain access to Rarity’s therapies for patient use, potentially supported by insurance reimbursement frameworks.

Partnerships may include collaborative development agreements and licensing deals, facilitating the distribution of their flagship gene therapies. The company is dedicated to establishing pricing models that reflect the value of their innovative treatments while ensuring that they remain accessible to patients in need. In October 2025, Rarity PBC raised USD 4. 6 mn in Seed funding, led by an individual investor.

The company plans to utilize these funds to accelerate the development of its main gene therapy targeting a rare immune disorder. Additionally, Rarity aims to expand into new markets, particularly in Europe and Asia, by 2026, to reach a broader patient base.